Pfizer Weighs Options For OTC Division As Investors Line Up For Purchase
This article was originally published in The Tan Sheet
Executive Summary
While Pfizer considers whether to sell its Consumer Healthcare unit or spin it off to shareholders, potential buyers are placing bids with an eye toward an early June deadline
You may also be interested in...
Liquid Rolaids Featured In Line’s Re-launch Into Crowded Antacid Market
Less than a year after Sanofi acquired Rolaids from Johnson & Johnson, its Chattem subsidiary reintroduces the antacid brand with tablet and liquid products in varying strengths. The liquid products could capitalize on Maalox and Mylanta missing from retail.
Liquid Rolaids Featured In Line’s Re-launch Into Crowded Antacid Market
Less than a year after Sanofi acquired Rolaids from Johnson & Johnson, its Chattem subsidiary reintroduces the antacid brand with tablet and liquid products in varying strengths. The liquid products could capitalize on Maalox and Mylanta missing from retail.
GSK Looks To Expand OTC Reach With CNS Brands
GlaxoSmithKline will pay nearly five times CNS's 12-month sales total to widen its consumer reach with the acquisition of CNS, the Minneapolis-based maker of Breathe Right and FiberChoice products